

Gareth Gerrard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4604582/publications.pdf>

Version: 2024-02-01

79
papers

2,772
citations

257450

24
h-index

175258

52
g-index

81
all docs

81
docs citations

81
times ranked

3654
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples. <i>Journal of Clinical Pathology</i> , 2022, 75, 241-249.	2.0	11
2	Assessment of quantitative polymerase chain reaction for <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?. <i>British Journal of Haematology</i> , 2022, 197, 52-62.	2.5	7
3	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3081-3089.	2.5	14
4	Alternative tissue fixation for combined histopathological and molecular analysis in a clinically representative setting. <i>Histochemistry and Cell Biology</i> , 2021, 156, 595-607.	1.7	1
5	Pushing the boundaries of in situ hybridisation for mRNA demonstration: demonstration of kappa and lambda light chain restriction in follicular lymphoma. <i>British Journal of Biomedical Science</i> , 2019, 76, 143-146.	1.3	1
6	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. <i>Haematologica</i> , 2019, 104, 2400-2409.	3.5	37
7	Targeted next generation sequencing of pancreatic solid pseudopapillary neoplasms show mutations in Wnt signaling pathway genes. <i>Pathology International</i> , 2019, 69, 193-201.	1.3	8
8	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. <i>Leukemia</i> , 2019, 33, 1910-1922.	7.2	54
9	Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?. <i>Oncotarget</i> , 2019, 10, 696-706.	1.8	6
10	Verteporfin Photodynamic therapy with 5 aza-deoxy-cytidine for neo-adjuvant treatment of primary breast cancer: Results of pre-clinical investigations. , 2019, , .		0
11	DNA-Based Digital PCR for the Quantification of Residual Disease in CML – Sensitivity or Specificity?. <i>Blood</i> , 2018, 132, 1738-1738.	1.4	0
12	Molecular and Cytogenetic Analysis. , 2017, , 126-164.		3
13	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , 2016, 30, 1844-1852.	7.2	51
14	Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia. <i>Leukemia Research</i> , 2016, 49, 47-50.	0.8	4
15	Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 176-189.	2.8	34
16	Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy. <i>Blood</i> , 2016, 128, 1223-1223.	1.4	2
17	Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Transcripts. Recommendations By the EUTOS Collaboration. <i>Blood</i> , 2016, 128, 1918-1918.	1.4	4
18	Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 65923-65936.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Differential Expression of Genes Associated with Oncogene-Induced Senescence and Senescence Associated Secretory Phenotype in the Absence of Differential Expression of High Molecular Risk Genes and Genes Associated with JAK-STAT Pathway in Sorted Cells of Patients with Polycythemia Vera and Primary Myelofibrosis. <i>Blood</i> , 2016, 128, 4283-4283.	1.4	0
20	Germline Calr exon 9 Variant and Somatic JAK2 V617F Mutation in a Patient with Polycythemia Vera Associated with Late Presentation and Severe Clinical Phenotype. <i>Blood</i> , 2016, 128, 5485-5485.	1.4	0
21	Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs. <i>Blood</i> , 2015, 125, 2553-2557.	1.4	33
22	A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. <i>Leukemia</i> , 2015, 29, 369-376.	7.2	72
23	<i>PTCH1</i> expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. <i>American Journal of Hematology</i> , 2015, 90, 20-26.	4.1	11
24	Targeted Sequencing of Sorted Peripheral Blood Cells Reveals Novel Germline and Somatic Variants in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 5213-5213.	1.4	1
25	Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2015, 126, 2794-2794.	1.4	0
26	DNA Methylation Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 5204-5204.	1.4	0
27	Gene Expression Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Polycythemia Vera and Primary Myelofibrosis. <i>Blood</i> , 2015, 126, 5201-5201.	1.4	0
28	Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. <i>British Journal of Haematology</i> , 2014, 164, 608-610.	2.5	3
29	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 843-850.	1.4	321
30	Real-time Quantification Assay to Monitor BCR-ABL1 Transcripts in Chronic Myeloid Leukemia. <i>Methods in Molecular Biology</i> , 2014, 1160, 115-124.	0.9	4
31	Prognostic Value of Multi-Drug Resistance 1 Gene (MDR1) Expression in Newly Diagnosed Patients with Chronic Myeloid Leukemia on Nilotinib Treatment—a Subanalysis of the ENEST1st Study. <i>Blood</i> , 2014, 124, 3144-3144.	1.4	1
32	Incidence of Vascular Thrombotic Events in 183 Consecutive Patients Treated with Nilotinib: A Single Centre Experience. <i>Blood</i> , 2014, 124, 3147-3147.	1.4	2
33	Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation. <i>Blood</i> , 2014, 124, 4557-4557.	1.4	0
34	A common novel splice variant of <i>SLC22A1</i> (<i>OCT1</i>) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 631-639.	2.5	33
35	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of <i>JAK2</i> , <i>V617F</i> and other relevant mutations. <i>British Journal of Haematology</i> , 2013, 160, 25-34.	2.5	87
36	Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia. <i>British Journal of Haematology</i> , 2013, 162, 530-536.	2.5	50

#	ARTICLE	IF	CITATIONS
37	Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. <i>Blood</i> , 2013, 121, 2739-2742.	1.4	85
38	NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA. <i>Blood</i> , 2013, 122, 4006-4006.	1.4	3
39	Dose Interruption/Reduction Of Tyrosine Kinase Inhibitors In The First 3 Months Of Treatment of CML Is Associated With Inferior Early Molecular Responses and Predicts For An Increased Likelihood Of Discontinuation Of The 1st Line Agent. <i>Blood</i> , 2013, 122, 93-93.	1.4	2
40	Targeted High-Throughput Sequencing For The Detection Of Mutations Associated With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 1613-1613.	1.4	0
41	The Depth Of "Complete"™ Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2013, 122, 5201-5201.	1.4	0
42	Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2012, 30, 232-238.	1.6	449
43	Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. <i>Blood</i> , 2012, 119, 1838-1843.	1.4	68
44	Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. <i>Blood</i> , 2012, 120, 697-698.	1.4	12
45	Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization. <i>American Journal of Hematology</i> , 2012, 87, 717-720.	4.1	14
46	<i>BCR-ABL1</i> kinase domain mutations: Methodology and clinical evaluation. <i>American Journal of Hematology</i> , 2012, 87, 298-304.	4.1	50
47	PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients. <i>Blood</i> , 2012, 120, 875-875.	1.4	0
48	Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?. <i>Blood</i> , 2012, 120, 68-68.	1.4	0
49	Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?. <i>Blood</i> , 2012, 120, 3760-3760.	1.4	0
50	Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.. <i>Blood</i> , 2012, 120, 2789-2789.	1.4	0
51	A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. <i>Blood</i> , 2012, 120, 2555-2555.	1.4	0
52	Target Enrichment and High-Throughput Sequencing of 80 Ribosomal Protein Genes to Identify Mutations Associated with Diamond-Blackfan Anaemia.. <i>Blood</i> , 2012, 120, 2369-2369.	1.4	0
53	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. <i>Blood</i> , 2011, 117, 3733-3736.	1.4	292
54	Guidelines for the measurement of <i>BCR-ABL1</i> transcripts in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 153, 179-190.	2.5	94

#	ARTICLE	IF	CITATIONS
55	Duplex quantitative PCR for molecular monitoring of <i>BCR-ABL1</i> -associated hematological malignancies. <i>American Journal of Hematology</i> , 2011, 86, 313-315.	4.1	10
56	Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. <i>Blood</i> , 2011, 118, 1680-1680.	1.4	3
57	The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for 'Stopping' Studies. <i>Blood</i> , 2011, 118, 605-605.	1.4	6
58	Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,. <i>Blood</i> , 2011, 118, 3777-3777.	1.4	5
59	EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. <i>Blood</i> , 2010, 116, 6014-6017.	1.4	29
60	Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. <i>British Journal of Haematology</i> , 2010, 148, 80-89.	2.5	147
61	Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. <i>Leukemia</i> , 2010, 24, 1817-1821.	7.2	9
62	hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. <i>Leukemia</i> , 2010, 24, 1243-1245.	7.2	43
63	Regulation of myeloid leukaemia by the cell-fate determinant Musashi. <i>Nature</i> , 2010, 466, 765-768.	27.8	315
64	Stability of Conversion Factors for BCR-ABL Monitoring - Implications for the Frequency of Validation Rounds. <i>Blood</i> , 2010, 116, 893-893.	1.4	16
65	Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.. <i>Blood</i> , 2010, 116, 3397-3397.	1.4	0
66	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , 2010, 116, 894-894.	1.4	1
67	The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. <i>Haematologica</i> , 2009, 94, 861-864.	3.5	12
68	Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. <i>European Journal of Pharmacology</i> , 2009, 609, 34-39.	3.5	12
69	Technical aspects and clinical applications of measuring <i>BCR-ABL1</i> transcripts number in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2009, 84, 517-522.	4.1	40
70	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.. <i>Blood</i> , 2009, 114, 3248-3248.	1.4	0
71	Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. <i>Leukemia</i> , 2008, 22, 1806-1807.	7.2	23
72	Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3113-3113.	1.4	0

#	ARTICLE	IF	CITATIONS
73	WT1 and PRAME Expression in CML: Quantitation by Real-Time PCR and Correlation with BCR-ABL Expression Levels. <i>Blood</i> , 2008, 112, 4225-4225.	1.4	0
74	Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1466-1466.	1.4	4
75	Glucosylceramide Synthetase Inhibitors Sensitise B-CLL Cells to Cytotoxic Agents without Reversing P-gp Functional Activity.. <i>Blood</i> , 2004, 104, 1181-1181.	1.4	0
76	Sequential Quantitative Minimal Residual Disease in BCR-ABL Positive Acute Lymphoblastic Leukaemia: Differential Observations between Major and Minor Fusion Gene Rearrangements and Variation Due to Source Material.. <i>Blood</i> , 2004, 104, 1093-1093.	1.4	0
77	Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. <i>Haematologica</i> , 2004, 89, 782-90.	3.5	66
78	Cytogenetics of multiple myeloma: interpretation of fluorescence <i>in situ</i> hybridization results. <i>British Journal of Haematology</i> , 2003, 120, 944-952.	2.5	32
79	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. <i>British Journal of Haematology</i> , 2002, 117, 427-435.	2.5	65